Rifaximin in the management of colonic diverticular disease

References

• Almy TP, Howell DA. Diverticular disease of the colon. N. Engl. J. Med.302, 324–331 (1980).
   PubMed Web of Science ®Google Scholar
• Petruzziello L, Iacopini F, Bulajic M, Shah S, Costamagna G. Review article: uncomplicated diverticular disease of the colon. Aliment Pharmacol. Ther.23, 1379–1391 (2006).
   PubMed Web of Science ®Google Scholar
• Humes D, Simpson J, Spiller RC. Colonic diverticular disease. Clin. Evid. 0405 (2007) (Epub ahead of print).
   Google Scholar
• Sheth AA, Longo W, Floch MH. Diverticular disease and diverticulitis. Am. J. Gastroenterol.103, 1550–1556 (2008).
   PubMed Web of Science ®Google Scholar
• Sandler RS, Everhart JE, Donowitz M et al. The burden of selected digestive diseases in the United States. Gastroenterology122, 1500–1511 (2002).
   PubMed Web of Science ®Google Scholar
• Ferzoco LB, Raptopoulos V, Silen W. Acute diverticulitis. N. Engl. J. Med.338, 1521–1526 (1998).
   PubMed Web of Science ®Google Scholar
• Kohler L, Sauerland S, Neugebauer E; Scientific Committee of the European Association for Endoscopic Surgery (EAES). Diagnosis and treatment of diverticular disease. Results of a consensus development conference. Surg. Endosc.13, 430–436 (1999).
   PubMed Web of Science ®Google Scholar
• Farrell RJ, Farrell JJ, Morrin MM. Diverticular disease in the elderly. Gastroenterol. Clin. North Am.30, 475–496 (2001).
   PubMed Web of Science ®Google Scholar
• Painter NS, Burkitt DP. Diverticular disease of the colon: a 20th Century problem. Clin. Gastroenterol.4, 3–21 (1974).
   Google Scholar
• Fisher N, Berry CS, Fearm T, Gregory JA, Hardy J. Cereal dietary fiber comsumption and diverticular disease: a lifespam study in rats. Am. J. Clin. Nutr.42, 788–804 (1985).
   PubMedGoogle Scholar
• Gear JS, Ware A, Fursdon P et al. Symptomless diverticular disease and intake of dietary fiber. Lancet1, 511–514 (1979).
   PubMed Web of Science ®Google Scholar
• Aldoori WH, Giovannucci EL, Rockett HR, Sampson L, Rimm EB, Willett WC. A prospective study of dietary fiber types and symptomatic diverticular disease in men. J. Nutr.128, 714–719 (1998).
   PubMed Web of Science ®Google Scholar
• Brodribb AJ. Treatment of symptomatic diverticular disease with high-fiber diet. Lancet1, 664–666 (1977).
   PubMed Web of Science ®Google Scholar
• Aldoori WH, Giovannucci EL, Rimm EB, Wing AL, Trichopoulos DV, Willett WC. A prospective study of diet and the risk of symptomatic diverticular disease in men. Am. J. Clin. Nutr.60, 757–764 (1994).
   PubMed Web of Science ®Google Scholar
• Ornestein MH, Littlewood ER, Baird IM, Fowlers J, Cox AG. Are fiber supplements really necessary in diverticular disease of the colon? A controlled clinical trial. Br. Med. J.282, 1353–1356 (1981).
   PubMedGoogle Scholar
• Hodgson WJB. The placebo effect: is it important in diverticular disease? Am. J. Gastroenterol.67, 157–162 (1977).
   PubMedGoogle Scholar
• Commane DM, Arasaradnam RP, Mills S, Mathers JC, Bradburn M. Diet, ageing and genetic factors in the pathogenesis of diverticular disease. World J. Gastroenterol.15, 2479–2488 (2009).
   PubMedGoogle Scholar
• Freeman HJ. Segmental colitis associated with diverticulosis syndrome. World J. Gastroenterol.14, 6442–6443 (2008).
   PubMedGoogle Scholar
• Stollmann NH, Raskin JB. Diagnosis and management of diverticular disease of the colon in adults. Am. J. Gastroenterol.94, 3110–3121 (1999).
   PubMedGoogle Scholar
• Floch MH, White JA. Management of diverticular disease is changing. World J. Gastroenterol.12, 3225–3228. (2006).
   PubMedGoogle Scholar
• Szojda MM, Cuesta MA, Mulder CM, Felt-Bersma RJ. Review article: management of diverticulitis. Aliment. Pharmacol. Ther.26(Suppl. 2), 67–76 (2007).
   PubMedGoogle Scholar
• Trivedi CD, Das KM. Emerging therapies for diverticular disease of the colon. J. Clin. Gastroenterol.42, 1145–1151 (2008).
   PubMedGoogle Scholar
• Tursi A, Papagrigoriadis S. Review article: the current and evolving treatment of colonic diverticular disease. Aliment. Pharmacol. Ther.30(6), 532–546 (2009).
   PubMed Web of Science ®Google Scholar
• Frieri G, Pimpo MT, Scarpignato C. Management of colonic diverticular disease. Digestion73(Suppl. 1), 58–66 (2006).
   PubMedGoogle Scholar
• Otte JJ, Larsen L, Anderson JR. Irritable bowel syndrome and symptomatic diverticular disease – different diseases? Am. J. Gastroenterol.81, 529–531 (1986).
   PubMedGoogle Scholar
• Schechter S, Mulvey J, Eisenstat TE. Management of uncomplicated acute diverticulitis. Results of a survey. Dis. Colon Rectum42, 470–476 (1999)
   PubMedGoogle Scholar
• Papi C, Koch M, Capurso L. Management of diverticular disease: is there room for rifaximin? Chemotherapy51(Suppl. 1), 110–114 (2005).
   PubMedGoogle Scholar
• Lin HC. Small intestinal bacterial overgrowth : a framework for understanding irritable bowel syndrome. JAMA292, 852–858 (2004).
   PubMed Web of Science ®Google Scholar
• Di Stefano M, Corazza GR. Treatment of small intestine bacterial overgrowth and related symptoms by rifaximin. Chemotherapy51(Suppl. 1), 103–109 (2005).
   PubMed Web of Science ®Google Scholar
• D’Incà R, Pomerri F, Vettorato MG et al. Interaction between rifaximin and dietary fiber in patients with diverticular disease. Aliment. Pharmacol. Ther.25, 771–779 (2007).
   PubMed Web of Science ®Google Scholar
• Husebye E. The pathogenesis of gastrointestinal bacterial overgrowth. Chemotherapy51(Suppl. 1), 1–22 (2005).
   PubMed Web of Science ®Google Scholar
• Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Assessment of small intestinal bacterial overgrowth in uncomplicated acute diverticulitis of the colon. World J. Gastroenterol.11, 2773–2776 (2005).
   PubMed Web of Science ®Google Scholar
• Rafferty J, Shellito P, Hyman NH, Buie WD; Standards Committee of the American Society of Colon and Rectum Surgeon. Practice parameters for sigmoid diverticulitis. Dis. Colon Rectum49, 939–944 (2006).
   PubMed Web of Science ®Google Scholar
• Hjern F, Josephson T, Altman D et al. Conservative treatment of acute colonic diverticulitis: are antibiotics always mandatory? Scand. J. Gastroenterol.42, 41–47 (2007).
   PubMed Web of Science ®Google Scholar
• Duma RJ, Kellum JM. Colonic diverticulitis: microbiologic, diagnostic and therapeutic considerations. Curr. Clin. Top. Infect. Dis.11, 218–247 (1991).
   PubMedGoogle Scholar
• Baker DE. Rifaximin: a nonabsorbed oral antibiotic. Rev. Gastroenterol. Disord.5, 19–30 (2005).
   PubMedGoogle Scholar
• Gillis JC, Brogden RN. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs49, 467–484 (1995).
   PubMed Web of Science ®Google Scholar
• Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy51(Suppl. 1), 36–66 (2005).
   PubMed Web of Science ®Google Scholar
• Jiang ZD, DuPont HL. Rifaximin: in vitro and in vivo antibacterial activity. Chemotherapy51(Suppl. 1), 67–72 (2005).
   PubMed Web of Science ®Google Scholar
• Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion73(Suppl. 1), 13–27 (2006).
   PubMed Web of Science ®Google Scholar
• Ojetti V, Lauritano EC, Barbaro F et al. Rifaximin pharmacology and clinical implications. Expert Opin. Drug Metab. Toxicol.5, 675–682 (2009).
   PubMed Web of Science ®Google Scholar
• Comparato G, Fanigliulo L, Aragona G et al. Quality of life in uncomplicated symptomatic diverticular disease: is it another good reason for treatment? Dig. Dis.25, 252–259 (2007).
   PubMedGoogle Scholar
• Othman M, Aguero R, Lin HC. Alteration in intestinal microbial flora and human disease. Curr. Opin. Gastroenterol.24, 11–16 (2008).
   PubMed Web of Science ®Google Scholar
• Brufani M, Cellai L, Marchi E, Segre A. The synthesis of 4-deoxypyrido [1´,2´-1,2]imidazo[5,4-c]rifamycin SV derivatives. J. Antibiot. (Tokyo)37, 1611–1622 (1984).
   PubMed Web of Science ®Google Scholar
• Marchi E, Montecchi L, Venturini AP, Mascellani G, Brufani M, Cellai L. 4-deoxypyrido [1´,2´-1,2]imidazo[5,4-c]rifamycin SV derivatives. A new series of semisynthetic rifamycins with high antibacterial activity and low gastroenteric absorption. J. Med. Chem.28, 960–963 (1985).
   PubMed Web of Science ®Google Scholar
• Brufani M, Cellai L, Cerrini S et al. X-ray crystal structure of 4-deoxy-3´-bromopyrido [1´,2´-1,2]imidazo[5,4-c] rifamycin SV. J. Antibiot. (Tokyo)37, 1623–1627 (1984).
   PubMed Web of Science ®Google Scholar
• Cellai L, Cerrini S, Segre A et al. A study of structure-activity relationships in 4-deoxypyrido [1´,2´-1,2]imidazo[5,4-c]rifamycin SV derivatives by electron spectroscopy for chemical analysis and 1H NMR. Mol. Pharmacol.27, 103–108 (1985).
   PubMed Web of Science ®Google Scholar
• Viscomi GC, Campana M, Barbanti M et al. Crystal forms of rifaximin and their effect on pharmaceutical properties. Cryst. Eng. Comm.10, 1074–1081 (2008).
   Google Scholar
• Jiang ZD, Ke S, Palazzini E, Riopel L, DuPont H. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob. Agents Chemother.44, 2205–2206 (2000).
   PubMed Web of Science ®Google Scholar
• Rizzello F, Gionchetti P, Venturi A et al. Rifaximin systemic absorption in patients with ulcerative colitis. Eur. J. Clin. Pharmacol.54, 91–93 (1998).
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Ferrieri A et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig. Dis. Sci.44, 1220–1221 (1999).
   PubMed Web of Science ®Google Scholar
• Dayan AD. Rifaximin (Normix) Preclinical Expert Report. Medicines and Healthcare Products Regulatory Agency, London, UK (1997).
   Google Scholar
• Verardi S, Verardi V. Bile rifaximin concentration after oral administration in patients undergoing cholecistectomy. Farmaco45, 131–135 (1990).
   PubMedGoogle Scholar
• Pentikis HS, Connolly M, Trapnell CB, Forbes WP, Bettenhausen DK. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. Pharmacotherapy27, 1361–1369 (2007).
   PubMed Web of Science ®Google Scholar
• Trapnell CB, Connolly M, Pentikis H, Forbes WP, Bettenhausen DK. Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. Ann. Pharmacother.41, 222–228 (2007).
   PubMed Web of Science ®Google Scholar
• De Leo C, Eftimiadi C, Schito GC. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drug Exp. Clin. Res.12, 979–981 (1986).
   PubMedGoogle Scholar
• Lombardo L, Lapertosa G. Medical treatment of outpatient diverticulitis of the colon: an open clinical-endoscopic histological study with a non-aminoglycoside entero-antibiotic-rifaximin (In Italian). Recenti. Prog. Med.82, 300–304 (1991).
   PubMedGoogle Scholar
• Papi C, Ciaco A, Koch M, Capurso L; Diverticular Disease Study Group. Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Ital. J. Gastroenterol.24, 452–456 (1992).
   PubMedGoogle Scholar
• Papi C, Ciaco A, Koch M, Capurso L. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. Aliment Pharmacol. Ther.9, 33–39 (1995).
   PubMedGoogle Scholar
• Latella G, Pimpo MT, Sottili S et al. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int. J. Colorectal. Dis.18, 55–62 (2003).
   PubMed Web of Science ®Google Scholar
• Colecchia A, Vestito A, Pasqui F et al. Efficacy of long-term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease. World J. Gastroenterol.13, 264–269 (2007).
   PubMed Web of Science ®Google Scholar
• Pimentel M. Review of rifaximin as treatment for SIBO and IBS. Expert Opin. Investig. Drugs18, 349–358 (2009).
   PubMed Web of Science ®Google Scholar
• Porta E, Germano A, Ferrieri A, Koch M. The natural history of diverticular disease of the colon: a role for antibiotics in preventing complications? A retrospective study. Eur. Rev. Med. Pharmacol. Sci.16, 33–39 (1994).
   Google Scholar
• Boirivant M, Amendola A, Butera A. Intestinal microflora and immunoregulation. Mucosal Immunol.1(Suppl. 1), S47–S49 (2008).
   Google Scholar
• Sheth A, Floch M. Probiotics and diverticular disease. Nutr. Clin. Pract.24, 41–44 (2009).
   PubMedGoogle Scholar
• Giaccari S, Tronci S, Falconieri M, Ferrieri A. Long-term treatment with rifaximin and lactobacilli in post-diverticulitic stenoses of the colon. Riv. Eur. Sci. Med. Farmacol.15, 29–34 (1993).
   PubMedGoogle Scholar
• Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. J. Clin. Gastroenterol.40, 312–316 (2006).
   PubMed Web of Science ®Google Scholar
• Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and/or Lactobacillus casei in maintaining long-term remission of symptomatic uncomplicated diverticular disease of the colon. Hepatogastroenterology55, 916–920 (2008).
   PubMedGoogle Scholar
• Tursi A, Brandimarte G, Giorgetti GM, Elisei W, Aiello F. Balsalazide and/or high-potency probiotic misture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. Int. J. Colorectal Dis.22, 1103–1108 (2007).
   PubMed Web of Science ®Google Scholar
• Brandimarte G, Tursi A. Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease. Med. Sci. Monit.10, 70–73 (2004).
   Web of Science ®Google Scholar
• Tursi A, Brandimarte G, Daffià R. Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. Dig. Liver Dis.34, 510–515 (2002).
   PubMedGoogle Scholar
• Di Mario F, Aragona G, Leandro G et al. Efficacy of mesalazine in the treatment of symptomatic diverticular disease. Dig. Dis. Sci.50, 581–586 (2005).
   PubMed Web of Science ®Google Scholar
• Comparato G, Fanigliulo L, Cavallaro LG et al. Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up. Dig. Dis. Sci.52, 2934–2941 (2007).
   PubMedGoogle Scholar
• Borelli G, Bertoli D. Acute, subacute, chronic toxicity and mutagenecity studies of rifaximin (L/105) in rats. Chemioterapia (Florence)5, 263–267 (1986).
   PubMedGoogle Scholar
• Bertoli D, Borelli G. Fertility study of rifaximin (L/105) in rats. Chemioterapia (Florence)5, 204–207 (1986).
   PubMedGoogle Scholar
• Fulcher SM. Rifaximin Combined Study of Effects on Fertility and Embryo–Fetal Toxicity in CD Rats by Oral Gavage Administration. Huntington Life Sciences, Suffolk, UK (2000).
   Google Scholar
• Zaniolo O, Eandi M. Rifaximin in treatment of diverticular disease: therapeutic and economic potential [in Italian]. Farmacoeconomia Percorsi Terapeutici6, 5–20 (2005).
   Google Scholar
• Khoshini R, Dai SC, Lezcano S, Pimentel M. A systemic review of diagnsostic tests for small intestinal bacterial overgrowth. Dig. Dis. Sci.53, 1443–1454 (2008).
   PubMed Web of Science ®Google Scholar
• Vanner S. The lactulose breath test for diagnosing SIBO in IBS patients: another nail in the coffin. Am. J. Gastroenterol.103, 958–963 (2008).
   PubMedGoogle Scholar
• Mac Mahon M, Gibbons N, Mullins E et al. Are hydrogen breath tests valid in the elderly? Gerontology42, 40–45 (1996).
   PubMedGoogle Scholar
• Tursi A, Brandimarte G, Elisei W et al. Assessment and grading of mucosal inflammation in colonic diverticular disease. J. Clin. Gastroenterol.42, 699–703 (2008).
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Vainer B, Rask-madsen J. Non-IBD and noninfectious colitis. Nat. Clin. Pract. Gastroenterol. Hepatol.5, 28–39 (2008).
   PubMedGoogle Scholar
• Morini S, Hassan C, Zullo A et al. Epithelial cell proliferation of the colonic mucosa in diverticular disease: a case-control study. Aliment Pharmacol. Ther.21, 1385–1390 (2005).
   PubMedGoogle Scholar
• Tursi A, Brandimarte G, Elisei W, Giorgetti GM, Inchingolo CD, Aiello F. Effect of mesalazine on epithelial cell proliferation in colonic diverticular disease. Dig. Liver Dis.40, 737–742 (2008).
   PubMedGoogle Scholar